Table 1. Relationship between cell-cycle phenotype and clinicopathological parameters.
| I (out-of-cycle) | II (in-cycle G1-delayed/arrested) | III (actively cycling) | |
|---|---|---|---|
| Mcm2 <30% | Mcm2 ⩾30% | Mcm2 ⩾30% | |
| Geminin <7% | Geminin ⩾7% | ||
| N=33 (18%) | N=44 (24%) | N=105 (58%) | |
| Age, mean (s.d.) (P=0.13) | 61.9 (12.4) | 61.2 (14.1) | 57.4 (13.9) |
| Grade (P<0.001)* | |||
| 1 | 27% (9/33) | 23% (10/44) | 5% (5/105) |
| 2 | 61% (20/33) | 64% (28/44) | 30% (32/105) |
| 3 | 12% (4/33) | 14% (6/44) | 65% (68/105) |
| Size, mean (s.d.) (P=0.55) | 24.7 (17.5) | 29.1 (19.8) | 28.0 (17.4) |
| Positive nodes (P=0.23) | 39% (12/31) | 33% (13/40) | 48% (47/98) |
| NPI, mean (s.d.) (P<0.001) | 3.8 (1.3) | 4.0 (1.2) | 4.9 (1.2) |
| ER+ casesa (P=0.08) | 100% (73.9–100%) | 100% (100–100%) | 88.9% (0–100%) |
| PR+ casesa (P=0.14) | 72.4% (35.8–100%) | 92.2% (47–100%) | 18.8% (0–97.8%) |
| Her-2 | |||
| 0 | 66.7% (22/33) | 68.2% (30/44) | 53.3% (56/105) |
| 1+ | 15.2% (5/33) | 18% (8/44) | 19% (20/105) |
| 2+ | 9.1% (3/33) | 4.5% (2/44) | 7.6% (8/105) |
| 3+ (P=0.45) | 9.1% (3/33) | 9.1% (4/44) | 20% (21/105) |
ER=oestrogen receptor; NPI=Nottingham Prognostic Index; PR=progesterone receptor.
aMedian (interquartile ranges).
*Significant association restricted to phenotype III.